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Abstract
Although 20-40% of persons with acute HCV infection demonstrate spontaneous clearance, the time-course and factors associated with clearance remain poorly understood. We investigated the time to spontaneous clearance and predictors among participants with acute HCV using Cox proportional hazards analyses. Data for this analysis were drawn from an international collaboration of nine prospective cohorts evaluating outcomes following acute HCV infection.
Among 632 participants with acute HCV, 35% were female, 82% were Caucasian, 49% had IL28B CC genotype (rs12979860), 96% had injected drugs ever, 47% were infected with HCV genotype 1 and 5% had HIV co-infection. Twenty-eight percent were HCV antibody Host factors such as female sex (1-4), immune responses (5, 6), virus-specific neutralizing antibodies (7) and host genetics (8, 9) have been associated with clearance in prospective studies of acute HCV infection. The strongest host factor associated with clearance is polymorphisms in the interleukin-28 (IL28B) gene region which encodes the interferon-λ3 protein (IFN-λ3, IFNL3) (8) (9) (10) and is involved in viral control (11) . Individuals with non-favourable IL28B genotypes (rs12979860 CT/TT alleles) are less likely to clear HCV infection compared to those with favorable genotypes (CC alleles) (4, 8, 9) . Pathogen factors, such as diversity of the HCV viral quasispecies (12) and HCV genotype (13) might also be linked with clearance. The majority of studies of people with acute HCV and clearance are limited by the small number of cases, which restricts statistical power, inference and generalizability.
The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC   3   ) Study, a collaborative of pooled data from nine prospective international cohorts mainly following PWID (14) , provides a unique opportunity to assess clearance in a large number of well characterized HCV-infected participants with prospective follow-up. The aim of this study was to investigate time to and predictors of clearance following acute HCV infection. The InC   3 Study, a collaboration of nine prospective cohorts evaluating HIV and HCV infection outcomes from Australia, Canada, the Netherlands, and the United States has been previously described (14) . All cohorts follow participants at regular intervals using standardized methods.
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METHODS
Study population and design
Participants were recruited and followed between 1985 and 2010. The InC For the current study, only individuals with documented acute HCV were included. Documented acute HCV is defined as either: 1) HCV seroconversion with an HCV antibody negative test followed by either an HCV antibody or RNA positive test within two years of the HCV antibody negative test; or 2) evidence of symptomatic HCV infection (defined by a positive HCV antibody/RNA test; jaundice or ALT elevation >400 U/L; and detection of HCV RNA or history of high-risk exposure within three months of clinical manifestation of acute HCV). Individuals who were HCV antibody negative/HCV RNA positive at the time of acute HCV detection (early acute HCV infection) were identified for sub-analyses, given the well-defined estimated time of infection in this sub-group. Individuals treated for HCV with an estimated duration of infection <26 weeks were excluded to reduce misclassification bias due to uncertainty around subsequent spontaneous clearance in the absence of treatment (n=37). All participants provided written informed consent and cohort protocols approved by local ethics committees.
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Laboratory testing
Choice of qualitative and quantitative HCV RNA testing varied by cohort but consistent at each site. Qualitative HCV RNA testing was performed using the following assays: Versant TMA [Bayer, Australia;<10 IU/ml], COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA;<15 IU/ml), COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostics, Mannheim, Germany; <50 IU/ml) or discriminatory HCV transcription-mediated amplification component of the Procleix HIV-1/HCV (Gen-Probe, San Diego, CA, USA; <12 copies/mL). Quantitative HCV RNA testing was performed using the Versant HCV RNA 3.0 (Bayer, Australia;<615 IU/ml), COBAS AMPLICOR HCV MONITOR 2.0 (Roche Diagnostics, Mannheim, Germany; <600 IU/ml), COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ, USA;<15 IU/ml) or an in-house PCR (<1000 IU/ml) (15, 16 
Estimating the date of acute HCV infection
The estimated date of acute HCV infection was calculated based on a hierarchy using the most the estimated date of infection was calculated as six weeks prior to its onset (jaundice or ALT >400 IU/mL) (19) . Among individuals with HCV seroconversion, the estimated date of infection was calculated as the mid-point between the last negative HCV antibody and first positive HCV antibody or RNA test. 
Study outcomes
Statistical analyses
Time to and predictors of clearance were assessed. Hypothesized predictors were determined a priori and included age (categorized as <30, 30-39 and >40 years) (20) , sex (1-4), symptomatic HCV infection (3, 8) , ethnicity (21) Cox proportional hazards analyses were used to identify predictors of clearance. In multivariate analyses, all variables with P<0.20 in unadjusted analysis were considered as potential independent predictors. Initial models were adjusted for age and built using a backwards stepwise approach with factors sequentially eliminated according to the result of the likelihood ratio test. Additional models were also considered using a shared 'frailty' random effect model to provide improved variance estimates and control for potential confounding by site.
Given previous data demonstrating an interaction between sex and IL28B genotype in HCV 
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Sensitivity analyses were performed to assess HCV time to and predictors of clearance among individuals with early acute HCV infection. All analyses were repeated using the mid-point estimation method for calculating the estimated date of HCV infection for those with symptomatic acute symptomatic infection and excluding participants receiving HCV treatment. Statistically significant differences were assessed at P<0.05; p-values are two-sided. All analyses were performed using Stata v12.0 (College Station, TX, United States).
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RESULTS
Participant characteristics
Among the 632 participants with acute HCV infection included, the median age was 26 years, 36% were female, 96% had a history of injecting drug use and 16% received HCV treatment during follow-up (all treated participants that were included started treatment at an estimated duration of infection >6 months) ( Among those with clearance, 34% (95%CI, 27%,42%, n=59) and 67% (95%CI, 60%,74%, n=116) had cleared infection by three months and six months following infection, respectively. At 12, 18 and 24 months following infection, 83% (95%CI, 77%,88%, n=144), 92% (95%CI, 87%,96%, n=160) and 97% (95%CI, 93%,99%, n=167) of those who did clear, had cleared infection. Among those with early acute HCV infection and clearance (n=43), the proportion of participants with clearance by 3, 6, 12, 18 and 24 months were 23% (95%CI, 12%,39%, n=10), 63% (95%CI, 47%,77%, n=27), 84% (95%CI, 69%,93%, n=36), 88% (95%CI, 75%,96%, n=38) and 93% (95%CI, 81%,99%, n=40). The rate of spontaneous clearance was 42 per 100 p-yrs (95%CI, 35,51) within the first six months of infection and 10 per 100 p-yrs (95%CI, 8,13) six months following infection.
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Factors predicting spontaneous clearance of acute HCV infection
In Kaplan-Meier and unadjusted Cox proportional hazards analyses, clearance was associated with female sex, symptomatic HCV infection, IL28B CC genotype and HCV genotype 1 ( Figure   2 , Table 2 ). Given that for 61% (n=383) of participants data were missing on symptomatic infection, this variable was not explored in multivariate analyses. Due to the a priori hypothesis that HCV genotype 1 would have higher clearance (13, 22) , the small numbers within some genotype categories (2/4/6/mixed) and the observation that all genotypes other than genotype 1 demonstrated lower clearance in unadjusted analysis ( Figure 3 ). In sensitivity analyses, results did not substantially change when analyses were restricted to individuals with early acute HCV infection, when the mid-point method was used to estimate the date of HCV infection or when participants treated for HCV infection were excluded (Supplementary Table 2 ). Adjustment for site also did not change the results ( Table 2 ).
The effect of sex and IL28B genotype on spontaneous clearance
Clearance rates were highest among females with the IL28B CC genotype ( Figure 4A ). After adjusting for age and HCV genotype (Table 3) , females with the IL28B CC genotype had the greatest probability of clearance as compared to males with the CT/TT genotype (AHR 4.65; (Table 3 ). The interaction between sex and IL28B was not significant on the multiplicative scale (P=0.265).
The effect of sex and HCV genotype on spontaneous clearance
Clearance rates were highest among females with HCV genotype 1 ( Figure 4B ). After adjusting for age and IL28B genotype (Table 3) , females with HCV genotype 1 had the greatest probability of clearance as compared to males with HCV genotype non-1 (AHR 3.30; 95%CI 1.94, 5.62,
P<0.001).
The AHR for males with the HCV genotype 1 was close to the AHR for female with HCV genotype non-1 ( Table 3 ). The interaction between sex and HCV genotype was not statistically significant on the multiplicative scale (P=0.560).
The effect of HCV genotype and IL28B genotype on spontaneous clearance
Clearance rates were lowest among individuals with HCV genotype non-1 and CT/TT IL28B genotype, ( Figure 4C ). After adjusting for age and sex ( The median time from the estimated date of infection to clearance was 16.5 weeks. This is longer than previously reported (8-11 weeks) (19, 24, 25) , but these studies had larger proportions of cases with symptomatic infection (19, 24, 25) . Consistent with another study (3), symptomatic infection was associated with clearance in this study. Unfortunately, the majority of cohorts in The finding that one-third of participants who demonstrated clearance did so more than six months following infection must be interpreted with caution. This is greater than reported in previous studies (19, 24, 25) . Although one explanation for this difference might be longer follow-up in InC 3 (19, 24, 25) , it is more likely that there is imprecise characterisation of time of clearance in InC 3 , particularly in cases with broader intervals of HCV RNA testing.
Female sex independently predicted spontaneous clearance, after adjusting for IL28B genotype and HCV genotype, consistent with previous reports (1-4) . The effect of IL28B genotype on clearance was greater among females than among males. While this is consistent with previous data demonstrating an interaction between female sex and IL28B genotype on clearance (4), this interaction was not statistically significant in the current study. The impact of HCV genotype 1 on clearance was also greater among females. This is consistent with very high proportions of females with clearance (52-54%) following HCV genotype 1 infection through contaminated anti-D immune globulin (26, 27) . Taken together, these results are striking and suggestive of the potential role of sex in modifying factors important in HCV clearance.
Mechanisms behind the association of female sex and clearance may be linked to sex-based differences in immunity. Females have a lower burden of infections (28), a higher prevalence of several autoimmune diseases (28) and an increased number and magnitude of immune and
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Hepatology inflammatory responses (29) , as compared to males. The prevailing hypothesis to explain immunological differences between males and females is that sex steroids bind to specific receptors expressed in lymphoid tissue cells, macrophages, dendritic cells and lymphocytes, thereby influencing the function of immune cells (29) . However, despite considerable research demonstrating differences in immune function between females and males, there are little data on sex-based differences in immune profiles in those with HCV. Further studies should focus on mechanisms explaining differences in clearance between males and females as this may contain important information for understanding HCV viral control. Limitations of previous studies include small numbers, the potential misclassification of genotype by HCV serotyping assays (13, 30) , the large proportion with an unknown HCV genotype status among those with clearance who could not be genotyped/serotyped and a lack of genotypic diversity in some groups (22) . Among studies that have investigated the impact of HCV genotype on spontaneous clearance, results are conflicting (13, 22, 30) , with some studies demonstrating lower (30), higher (13, 22) There are several limitations to this study. Nine cohorts of individuals with acute HCV (mainly PWID) were combined. Participating cohorts bring a range of data types and structures presenting issues surrounding both inconsistent measurement and biological data testing protocols (e.g. HCV RNA assays differed across cohorts). As such, there was some heterogeneity across the cohorts with respect to the availability of data on certain variables known to be associated with clearance (e.g. symptomatic infection) and it was not possible to adjust our analyses for these factors. The availability of only one HCV RNA negative test at last follow-up limited the ability to assess late clearance outcome in a small minority (<5%). In contrast, some instances of late clearance may be due to very early clearance and subsequent reinfection (with clearance of the second infection detected) (32) . Broad intervals of HCV RNA testing in some individuals reduced the precision of estimated time of clearance. There were also small numbers for some categorized variables in this study (HIV and ethnicity) and the absence 
